Skip to main content
SpringerLink
Log in

Clinical Trials for Parkinson’s Disease

  • Chapter
Drugs for the Treatment of Parkinson’s Disease

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 88))

  • 311 Accesses

Abstract

Anticholinergic agents have been used for over 100 years for treating Parkinson’s disease and clinical trials have been reported since the late nineteenth century (Aquilonius 1979). In the past two decades more drug studies have been conducted in Parkinson’s disease than in any other neurological disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Armitage P (1957) Restricted sequential procedures. Biometrics 44: 9–26

    Google Scholar 

  • Armitage P (1960) Sequential medical trials. Blackwell, Oxford

    Google Scholar 

  • Aquilonius S-M (1979) Cholinergic mechanisms in the CNS related to Parkinson’s disease. In: Rinne UK, Klingler M, Stamm G (eds) Parkinson’s disease current progress, problems and management. Elsevier, North-Holland, Amsterdam, pp 17–27

    Google Scholar 

  • Barbeau A (1961) Biochemistry of Parkinson’s disease. In: Proceedings of the seventh international congress of neurology, Rome, Sept, Societa Grafica Romana, Rome, vol 2, p 925

    Google Scholar 

  • Barbeau A (1969) L-Dopa therapy in Parkinson’s disease: a critical review of nine years’ experience. Can Med. Assoc J. 101: 791–800

    Google Scholar 

  • Barbeau A Roy M (1976) Six-year results of treatment with levodopa plus benzerazide in Parkinson’s disease. Neurology (NY) 267: 399–404

    Google Scholar 

  • Birkmayer W, Hornykiewicz O (1966) Der L-3,4-Dioxyphenylalanin (=DOPA)-Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 73: 787–788

    Google Scholar 

  • Birkmayer W, Hornykiewicz O (1962) Der L-Dioxyphenylalanin (= L-DOPA)-Effekt beim Parkinson-Syndrom des Menschen: zur Pathogenese und Behandlung der Parkinson-Akinese. Arch Psychiatr Nervenkr 203: 560–574

    Article  CAS  Google Scholar 

  • Birkmayer W, Riederer P, Ambrozi L, Youdim MBH (1977) Implications of combined treatment with “Madopar” and L-deprenyl in Parkinson’s disease. Lancet 1: 439–443

    Article  PubMed  CAS  Google Scholar 

  • Calne DB, Teychenne PF, Claveria LE, Eastman R, Greenacre JK, Petrie A (1974). Bromocriptine in parkinsonism. Br Med J 4: 442–444

    Article  PubMed  CAS  Google Scholar 

  • Canter GJ, deLa Torre R, Mier M (1961) A method for evaluating disability in patients with Parkinson’s disease. J Nerv Ment Dis 133: 143–147

    Article  PubMed  CAS  Google Scholar 

  • Cotzias GC, Papavasilou PS, Gellene R (1969) Modification of parkinsonism—chronic treatment with L-dopa. N Engl J Med 280: 337–345

    Article  PubMed  CAS  Google Scholar 

  • Donaldson J, LaBella FS, Gesser D (1980) Enhanced autoxidation of dopamine as a possible basis of manganese neurotoxicity. Neurotoxicology (Park Forest II ) 2: 53–64

    Google Scholar 

  • Duvoisin RC (1970) The evaluation of extra-pyramidal disease. In: de Ajuriagerra J (ed) Monoamines: noyaux gris centraux et syndrome de Parkinson. Masson, Paris, pp 313–325

    Google Scholar 

  • Eisler T, Thorner MO, MacLeod RM, Kaiser DL, Calne DB (1981) Prolactin secretion in Parkinson’s disease. Neurology (NY) 31: 1356–1359

    CAS  Google Scholar 

  • England AC, Schwab RS (1956) Post-operative evaluation of selected patients with Parkinson’s disease. J Am Geriatr Soc 4: 1219–1232

    PubMed  Google Scholar 

  • Evarts EV, Teravainen H, Calne DB (1981) Reaction time in Parkinson’s disease. Brain 106: 167–186

    Article  Google Scholar 

  • Fienbery SE (1983) The analysis of cross-classified categorial data, 2nd edn. MIT Press, Cambridge

    Google Scholar 

  • Folkerts JF, Njiokiktjien CJ (1971) The influence of L-dopa on the postural regulation of Parkinson patients. 1st Symposium international de posturographie, Madrid, 19–22 Oct

    Google Scholar 

  • Hietanen M, Teravainen H, Tsui JK, Calne DB (1987) The pegboard as a measurement of parkinsonian motor deficit. Neurology 37 (Suppl 1): 266

    Google Scholar 

  • Hoaglin DC, Mosteller F, Tukey JW (1983) Understanding robust and exploratory data analysis. Wiley, New York

    Google Scholar 

  • Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology (NY) 17: 427–442

    CAS  Google Scholar 

  • Jansen EC, Larsen RE, Olesen MB (1982) Quantitative Romberg’s test. Acta Neurol Scand 66: 93–99

    Article  PubMed  CAS  Google Scholar 

  • Kartzinel R, Perlow MD, Carter AC, Chase TN, Calne DB, Shoulson I (1976) Metabolic studies with bromocriptine in patients with idiopathic parkinsonism and Huntington’s chorea. Trans Am Neurol Assoc 101: 53–56

    PubMed  CAS  Google Scholar 

  • Knopp W (1968) Explorations in the assessment and meaning of the subclinical extrapyramidal effect of neuroleptic drugs. Pharmakopsychiatria Neuropsychopharmakol 1: 54–62

    Google Scholar 

  • Knutsson E (1972) An analysis of parkinsonian gait. Brain 95: 475–486

    Article  PubMed  CAS  Google Scholar 

  • Lakke JPWF, Korf J, Van Praag HM, Schut T (1972) Predictive value of the probenecid test for the effect of L-dopa therapy in Parkinson’s disease. Nature New Biol 236: 208–209

    PubMed  CAS  Google Scholar 

  • Larsen TA, LeWitt PA, Calne DB (1983) Theoretical and practical issues in assessment of deficits and therapy in parksinsonism. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 363–373

    Google Scholar 

  • Larsen TA, Calne S, Calne DB (1984) Assessment of Parkinson’s disease. Clin Neuropharmacol 7 (2): 165–169

    Article  PubMed  CAS  Google Scholar 

  • Lieberman A, Dziatolowski M, Gopinathan G, Kupersmith M, Neophytides A, Korein J (1980) Evaluation of Parkinson’s disease. In: Goldstein M, Calne DB, Lieberman A, Thorner MO (eds) Ergot compounds and brain function: neuroendocrine and neuropsychiatric aspects. Raven, New York, pp 277–286

    Google Scholar 

  • Lyman O (1984) An introduction to statistical methods and data analysis, 2nd ed Duxbury, Boston

    Google Scholar 

  • Markham CH, Diamond SG (1981) Evidence to support early levodopa therapy in Parkinson’s disease. Neurology (NY) 31: 125–131

    CAS  Google Scholar 

  • Martin WRW, Stoessl AJ, Adam MJ, Ammann W, Bergstrom M, Harrop R, Laihinen A, Rogers JG, Ruth TJ, Sayre CI, Pate BD, Calne DB (1986) Positron emission tomography in Parkinson’s disease: glucose and DOPA metabolism. Adv Neurol 45: 95–101

    Google Scholar 

  • Parkes JD, Curzon G, Knott PJ, Tattersall R, Baxter RCH, Knill-Jones RP, Marsden CD, Vollum D (1971) Treatment of Parkinson’s disease with amantadine and levodopa. Lancet 1: 1083–1086

    Article  PubMed  CAS  Google Scholar 

  • Schoenberg BS, Anderson DW, Haerer AF (1986) Racial differentials in the prevalence of Parkinson’s disease. Neural 36: 841–845

    Google Scholar 

  • Shoulson I, The Parkinson Sindy Group (1987). Correlates of clinical decline in early Parkinson’s disease (ABST). Neurology 37 (Suppl 1): 278

    Google Scholar 

  • Stoessl AJ, Mak E, Calne DB (1985) (+)-4-propyl-9-hydroxynaphthoxazine ( PHNO), a new dopaminomimetic, in treatment of parkinsonism. Lancet ii: 1130–1331

    Google Scholar 

  • Tatton WG, Eastman MJ, Bedingham W, Verrier MC, Bruce IC (1984) Defective utilization of sensory input as the basis for bradykinesia, rigidity and decreased movement repertoire in Parkinson’s disease: a hypothesis. Can J Neurol Sci 11: 136–143

    PubMed  CAS  Google Scholar 

  • Teräväinen H, Calne DB (1980) Quantitative assessment of Parkinsonian deficits. In: Rinne UK, Klingler M, Stamm G (eds) Parkinson’s disease: current progress, problems and management. Elsevier, North-Holland, Amsterdam, pp 145–164

    Google Scholar 

  • Teräväinen H, Evarts EV, Calne DB (1980) Studies of parkinsonian movement. 1. Programming and execution of eye movements. Acta Neurol Scand 62: 137–148

    Article  PubMed  Google Scholar 

  • Wagner HN, Burns HD, Dannais RF, Wong DF, Langstrom B, Duelfer T, Frost JJ, Ravart HT, Links JM, Rosenbloom SB, Lukas SE, Kramer AV, Kuhar MJ (1983) Imaging dopamine receptors in the human brain by positron tomography. Science 221: 264–1266

    Article  Google Scholar 

  • Ward CD, Sanes JN, Dambrosia JM, Calne DB (1983) Methods for evaluating treatment in Parkinson’s disease. Adv Neurol 37: 1–7

    PubMed  CAS  Google Scholar 

  • Webster DD (1968) Critical analysis of the disability in Parkinson’s disease. Mod Treat 5: 257–282

    PubMed  CAS  Google Scholar 

  • Webster DD, Mortimer JA (1977) Failure of L-dopa to relieve activated rigidity in Parkinson’s disease. In: Messiha FS, Kenny AD (eds) Parkinson’s disease. Neurophysiological, clinical and related aspects, Plenum, New York, pp 297–313.

    Google Scholar 

Download references

Authors
  1. J. K. Tsui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Teräväinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. B. Calne
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Neurology, UBC Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia, Canada, V6T 1W5

    Donald B. Calne Professor D.M., F.R.C.P., F.R.C.P.C. (Head) (Head)

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Tsui, J.K., Teräväinen, H., Calne, D.B. (1989). Clinical Trials for Parkinson’s Disease. In: Calne, D.B. (eds) Drugs for the Treatment of Parkinson’s Disease. Handbook of Experimental Pharmacology, vol 88. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73899-9_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-73899-9_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-73901-9

  • Online ISBN: 978-3-642-73899-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation